{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T21:04:03Z","timestamp":1762376643793},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s11606-019-05384-x","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T22:15:36Z","timestamp":1571350536000},"page":"276-282","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["At Odds About the Odds: Women\u2019s Choices to Accept Osteoporosis Medications Do Not Closely Agree with Physician-Set Treatment Thresholds"],"prefix":"10.1007","volume":"35","author":[{"given":"Emma O.","family":"Billington","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Lynn","family":"Feasel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory A.","family":"Kline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,17]]},"reference":[{"issue":"26","key":"5384_CR1","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMp1504245","volume":"372","author":"Peter A. Ubel","year":"2015","unstructured":"Ubel PA. Medical Facts versus Value Judgements - Toward Preference-Sensitive Guidelines. N Engl J Med. 2015;372(26). \nhttps:\/\/doi.org\/10.1056\/NEJMp1504245","journal-title":"New England Journal of Medicine"},{"issue":"7182","key":"5384_CR2","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1136\/bmj.318.7182.527","volume":"318","author":"SH Woolf","year":"1999","unstructured":"Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ. 1999;318(7182):527-30. \nhttps:\/\/doi.org\/10.1136\/bmj.318.7182.527","journal-title":"BMJ."},{"issue":"17","key":"5384_CR3","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1503\/cmaj.100771","volume":"182","author":"A Papaioannou","year":"2010","unstructured":"Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010;182(17):1864-73. \nhttps:\/\/doi.org\/10.1503\/cmaj.100771","journal-title":"CMAJ."},{"issue":"10","key":"5384_CR4","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician\u2019s Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int 2014;25(10):2359-81. \nhttps:\/\/doi.org\/10.1007\/s00198-014-2794-2","journal-title":"Osteoporos Int"},{"issue":"6","key":"5384_CR5","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/joim.12339","volume":"277","author":"IR Reid","year":"2015","unstructured":"Reid IR. Efficacy, effectiveness and side effects of medications used to prevent fractures. J Intern Med 2015;277(6):690-706. \nhttps:\/\/doi.org\/10.1111\/joim.12339","journal-title":"J Intern Med"},{"issue":"5","key":"5384_CR6","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s00198-011-1630-1","volume":"23","author":"WD Leslie","year":"2012","unstructured":"Leslie WD, Giangregorio LM, Yogendran M, Azimaee M, Morin S, Metge C, et al. A population-based analysis of the post-fracture care gap 1996-2008: the situation is not improving. Osteoporos Int 2012;23(5):1623-9. \nhttps:\/\/doi.org\/10.1007\/s00198-011-1630-1","journal-title":"Osteoporos Int"},{"key":"5384_CR7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s11657-013-0144-1","volume":"8","author":"JA Kanis","year":"2013","unstructured":"Kanis JA, Borgstrom F, Compston J, Dreinhofer K, Nolte E, Jonsson L, et al. SCOPE: a scorecard for osteoporosis in Europe. Arch Osteoporos 2013;8:144. \nhttps:\/\/doi.org\/10.1007\/s11657-013-0144-1","journal-title":"Arch Osteoporos"},{"issue":"9","key":"5384_CR8","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1002\/jbmr.2202","volume":"29","author":"DH Solomon","year":"2014","unstructured":"Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res 2014;29(9):1929-37. \nhttps:\/\/doi.org\/10.1002\/jbmr.2202","journal-title":"J Bone Miner Res"},{"issue":"8","key":"5384_CR9","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.4065\/81.8.1013","volume":"81","author":"ES Siris","year":"2006","unstructured":"Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81(8):1013-22. \nhttps:\/\/doi.org\/10.4065\/81.8.1013","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"5384_CR10","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00198-011-1645-7","volume":"23","author":"AM Burden","year":"2012","unstructured":"Burden AM, Paterson JM, Solomon DH, Mamdani M, Juurlink DN, Cadarette SM. Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada. Osteoporos Int 2012;23(3):1075-82. \nhttps:\/\/doi.org\/10.1007\/s00198-011-1645-7","journal-title":"Osteoporos Int"},{"issue":"4","key":"5384_CR11","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s00198-016-3886-y","volume":"28","author":"A Modi","year":"2017","unstructured":"Modi A, Sajjan S, Insinga R, Weaver J, Lewiecki EM, Harris ST. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years. Osteoporos Int 2017;28(4):1355-63. \nhttps:\/\/doi.org\/10.1007\/s00198-016-3886-y","journal-title":"Osteoporos Int"},{"issue":"9","key":"5384_CR12","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.amjmed.2011.12.013","volume":"125","author":"SH Naderi","year":"2012","unstructured":"Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 2012;125(9):882-7 e1. \nhttps:\/\/doi.org\/10.1016\/j.amjmed.2011.12.013","journal-title":"Am J Med"},{"issue":"10","key":"5384_CR13","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1001\/archinte.165.10.1147","volume":"165","author":"RH Chapman","year":"2005","unstructured":"Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;165(10):1147-52. \nhttps:\/\/doi.org\/10.1001\/archinte.165.10.1147","journal-title":"Arch Intern Med"},{"issue":"1","key":"5384_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1001\/archinte.160.1.41","volume":"160","author":"TJ Bungard","year":"2000","unstructured":"Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why Do Patients With Atrial Fibrillation Not Receive Warfarin? Arch Intern Med 2000;160(1):41. \nhttps:\/\/doi.org\/10.1001\/archinte.160.1.41","journal-title":"Arch Intern Med"},{"issue":"3","key":"5384_CR15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/fampra\/18.3.309","volume":"18","author":"AA Montgomery","year":"2001","unstructured":"Montgomery AA, Harding J, Fahey T. Shared decision making in hypertension: the impact of patient preferences on treatment choice. Fam Pract 2001;18(3):309-13.","journal-title":"Fam Pract"},{"issue":"4","key":"5384_CR16","first-page":"403","volume":"163","author":"FA McAlister","year":"2000","unstructured":"McAlister FA, Connor AM, Wells G, Grover SA, Laupacis A. When should hypertension be treated? The different perspectives of Canadian family physicians and patients. Can Med Assoc J 2000;163(4):403.","journal-title":"Can Med Assoc J"},{"issue":"7247","key":"5384_CR17","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1136\/bmj.320.7247.1446","volume":"320","author":"N Steel","year":"2000","unstructured":"Steel N. Thresholds for taking antihypertensive drugs in different professional and lay groups: questionnaire survey. Bmj. 2000;320(7247):1446-7. \nhttps:\/\/doi.org\/10.1136\/bmj.320.7247.1446","journal-title":"Bmj."},{"issue":"1","key":"5384_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jocd.2011.07.008","volume":"15","author":"JM Neuner","year":"2012","unstructured":"Neuner JM, Schapira MM. The importance of physicians\u2019 risk perception in osteoporosis treatment decision making. J Clin Densitom 2012;15(1):49-54. \nhttps:\/\/doi.org\/10.1016\/j.jocd.2011.07.008","journal-title":"J Clin Densitom"},{"issue":"4","key":"5384_CR19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.japh.2017.05.003","volume":"57","author":"SF Hall","year":"2017","unstructured":"Hall SF, Edmonds SW, Lou Y, Cram P, Roblin DW, Saag KG, et al. Patient-reported reasons for nonadherence to recommended osteoporosis pharmacotherapy. J Am Pharm Assoc (2003). 2017;57(4):503-9. \nhttps:\/\/doi.org\/10.1016\/j.japh.2017.05.003","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"1","key":"5384_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11657-016-0272-5","volume":"11","author":"BR Lindsay","year":"2016","unstructured":"Lindsay BR, Olufade T, Bauer J, Babrowicz J, Hahn R. Patient-reported barriers to osteoporosis therapy. Arch Osteoporos 2016;11(1):1-8.","journal-title":"Arch Osteoporos"},{"issue":"2","key":"5384_CR21","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s11606-007-0490-z","volume":"23","author":"CA Sinsky","year":"2008","unstructured":"Sinsky CA, Foreman-Hoffman V, Cram P. The impact of expressions of treatment efficacy and out-of-pocket expenses on patient and physician interest in osteoporosis treatment: implications for pay-for-performance programs. J Gen Intern Med 2008;23(2):164-8. \nhttps:\/\/doi.org\/10.1007\/s11606-007-0490-z","journal-title":"J Gen Intern Med"},{"issue":"2","key":"5384_CR22","doi-asserted-by":"publisher","first-page":"e013703","DOI":"10.1136\/bmjopen-2016-013703","volume":"7","author":"R Kalluru","year":"2017","unstructured":"Kalluru R, Petrie KJ, Grey A, Nisa Z, Horne AM, Gamble GD, et al. Randomised trial assessing the impact of framing of fracture risk and osteoporosis treatment benefits in patients undergoing bone densitometry. BMJ Open 2017;7(2):e013703. \nhttps:\/\/doi.org\/10.1136\/bmjopen-2016-013703","journal-title":"BMJ Open"},{"issue":"3","key":"5384_CR23","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.ijcard.2014.07.219","volume":"176","author":"H Wouters","year":"2014","unstructured":"Wouters H, Van Dijk L, Van Geffen EC, Geers HC, Souverein PC, Bouvy ML, et al. Do the benefits of statins outweigh their drawbacks? Assessing patients\u2019 trade-off preferences with conjoint analysis. Int J Cardiol 2014;176(3):1220-2. \nhttps:\/\/doi.org\/10.1016\/j.ijcard.2014.07.219","journal-title":"Int J Cardiol"},{"key":"5384_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2474-4-17","volume":"4","author":"TM Winzenberg","year":"2003","unstructured":"Winzenberg TM, Oldenburg B, Frendin S, Jones G. The design of a valid and reliable questionnaire to measure osteoporosis knowledge in women: the Osteoporosis Knowledge Assessment Tool (OKAT). BMC Musculoskelet Disord 2003;4:17. \nhttps:\/\/doi.org\/10.1186\/1471-2474-4-17","journal-title":"BMC Musculoskelet Disord"},{"issue":"8","key":"5384_CR25","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/jbmr.2888","volume":"31","author":"S Khosla","year":"2016","unstructured":"Khosla S, Shane E. A Crisis in the Treatment of Osteoporosis. J Bone Miner Res 2016;31(8):1485-7. \nhttps:\/\/doi.org\/10.1002\/jbmr.2888","journal-title":"J Bone Miner Res"},{"issue":"6","key":"5384_CR26","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s00198-017-3986-3","volume":"28","author":"SR Majumdar","year":"2017","unstructured":"Majumdar SR, Lier DA, Hanley DA, Juby AG, Beaupre LA, Team S-P. Economic evaluation of a population-based osteoporosis intervention for outpatients with non-traumatic non-hip fractures: the \u201cCatch a Break\u201d 1i [type C] FLS. Osteoporos Int 2017;28(6):1965-77. \nhttps:\/\/doi.org\/10.1007\/s00198-017-3986-3","journal-title":"Osteoporos Int"},{"issue":"5","key":"5384_CR27","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/jbmr.3395","volume":"33","author":"MI Danila","year":"2018","unstructured":"Danila MI, Outman RC, Rahn EJ, Mudano AS, Redden DT, Li P, et al. Evaluation of a Multimodal, Direct-to-Patient Educational Intervention Targeting Barriers to Osteoporosis Care: A Randomized Clinical Trial. J Bone Miner Res 2018;33(5):763-72. \nhttps:\/\/doi.org\/10.1002\/jbmr.3395","journal-title":"J Bone Miner Res"},{"issue":"12","key":"5384_CR28","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1007\/s00198-016-3681-9","volume":"27","author":"P Cram","year":"2016","unstructured":"Cram P, Wolinsky FD, Lou Y, Edmonds SW, Hall SF, Roblin DW, et al. Patient-activation and guideline-concordant pharmacological treatment after bone density testing: the PAADRN randomized controlled trial. Osteoporos Int 2016;27(12):3513-24. \nhttps:\/\/doi.org\/10.1007\/s00198-016-3681-9","journal-title":"Osteoporos Int"},{"issue":"6","key":"5384_CR29","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.amjmed.2011.01.013","volume":"124","author":"VM Montori","year":"2011","unstructured":"Montori VM, Shah ND, Pencille LJ, Branda ME, Van Houten HK, Swiglo BA, et al. Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial. Am J Med 2011;124(6):549-56. \nhttps:\/\/doi.org\/10.1016\/j.amjmed.2011.01.013","journal-title":"Am J Med"},{"issue":"5","key":"5384_CR30","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1177\/0272989X07306784","volume":"27","author":"L Fraenkel","year":"2007","unstructured":"Fraenkel L, McGraw S. Participation in medical decision making: the patients\u2019 perspective. Med Decis Mak 2007;27(5):533-8. \nhttps:\/\/doi.org\/10.1177\/0272989X07306784","journal-title":"Med Decis Mak"},{"issue":"1","key":"5384_CR31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00198-016-3693-5","volume":"28","author":"LA Wozniak","year":"2017","unstructured":"Wozniak LA, Johnson JA, McAlister FA, Beaupre LA, Bellerose D, Rowe BH, et al. Understanding fragility fracture patients\u2019 decision-making process regarding bisphosphonate treatment. Osteoporos Int 2017;28(1):219-29. \nhttps:\/\/doi.org\/10.1007\/s00198-016-3693-5","journal-title":"Osteoporos Int"},{"issue":"4","key":"5384_CR32","doi-asserted-by":"publisher","first-page":"e18468","DOI":"10.1371\/journal.pone.0018468","volume":"6","author":"EA Scoville","year":"2011","unstructured":"Scoville EA, Ponce de Leon Lovaton P, Shah ND, Pencille LJ, Montori VM. Why do women reject bisphosphonates for osteoporosis? A videographic study. PLoS One. 2011;6(4):e18468. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0018468","journal-title":"PLoS One"},{"issue":"3","key":"5384_CR33","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/jamainternmed.2015.6020","volume":"176","author":"JJ Fenton","year":"2016","unstructured":"Fenton JJ, Robbins JA, Amarnath AD, Franks P. Osteoporosis overtreatment in a regional health care system. JAMA Intern Med 2016;176(3):391-3. \nhttps:\/\/doi.org\/10.1001\/jamainternmed.2015.6020","journal-title":"JAMA Intern Med"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-019-05384-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11606-019-05384-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-019-05384-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T00:06:56Z","timestamp":1602893216000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11606-019-05384-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,17]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["5384"],"URL":"https:\/\/doi.org\/10.1007\/s11606-019-05384-x","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,17]]},"assertion":[{"value":"3 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed consent was obtained from all participants prior to study enrollment, and the study received approval from the local Health Research Ethics Board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"EOB reports receiving honoraria from Eli Lilly and Amgen for serving on their Scientific Advisory Boards, and has received research funding from Amgen. All remaining authors declare that they do not have a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}